Ginkgo Bioworks Holdings Inc

NYSE:DNAUnited States

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.

Contact Information

Headquarters

27 Drydock Avenue, 8Th FloorBOSTON, MA, United States 02210

Phone

310-209-7280

Fax

302-655-5049

Executives

President, Founder, Chief Operating Officer, Director

Reshma Shetty

Chief Executive Officer, Founder, Director

Jason Kelly

Chief Financial Officer

Mark Dmytruk

Director

Marijn Dekkers

Independent Director

Arie Belldegrun